166 related articles for article (PubMed ID: 23028998)
41. Regulation of lymphocyte apoptosis by interferon regulatory factor 4 (IRF-4).
Fanzo JC; Hu CM; Jang SY; Pernis AB
J Exp Med; 2003 Feb; 197(3):303-14. PubMed ID: 12566414
[TBL] [Abstract][Full Text] [Related]
42. Evaluation of the in vitro and in vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma.
Dalgard CL; Van Quill KR; O'Brien JM
Clin Cancer Res; 2008 May; 14(10):3113-23. PubMed ID: 18483379
[TBL] [Abstract][Full Text] [Related]
43. Histone deacetylase activity is required to recruit RNA polymerase II to the promoters of selected interferon-stimulated early response genes.
Sakamoto S; Potla R; Larner AC
J Biol Chem; 2004 Sep; 279(39):40362-7. PubMed ID: 15194680
[TBL] [Abstract][Full Text] [Related]
44. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
[TBL] [Abstract][Full Text] [Related]
45. Discovery of a tetrahydroisoquinoline-based hydroxamic acid derivative (ZYJ-34c) as histone deacetylase inhibitor with potent oral antitumor activities.
Zhang Y; Fang H; Feng J; Jia Y; Wang X; Xu W
J Med Chem; 2011 Aug; 54(15):5532-9. PubMed ID: 21714538
[TBL] [Abstract][Full Text] [Related]
46. Unphosphorylated STAT1 promotes sarcoma development through repressing expression of Fas and bad and conferring apoptotic resistance.
Zimmerman MA; Rahman NT; Yang D; Lahat G; Lazar AJ; Pollock RE; Lev D; Liu K
Cancer Res; 2012 Sep; 72(18):4724-32. PubMed ID: 22805310
[TBL] [Abstract][Full Text] [Related]
47. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
[TBL] [Abstract][Full Text] [Related]
48. The inhibitor of growth 1 (ING1) is involved in trichostatin A-induced apoptosis and caspase 3 signaling in p53-deficient glioblastoma cells.
Tamannai M; Farhangi S; Truss M; Sinn B; Wurm R; Bose P; Henze G; Riabowol K; von Deimling A; Tallen G
Oncol Res; 2010; 18(10):469-80. PubMed ID: 20681406
[TBL] [Abstract][Full Text] [Related]
49. Isolation and characterization of a human STAT1 gene regulatory element. Inducibility by interferon (IFN) types I and II and role of IFN regulatory factor-1.
Wong LH; Sim H; Chatterjee-Kishore M; Hatzinisiriou I; Devenish RJ; Stark G; Ralph SJ
J Biol Chem; 2002 May; 277(22):19408-17. PubMed ID: 11909852
[TBL] [Abstract][Full Text] [Related]
50. Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression.
Palani CD; Beck JF; Sonnemann J
Invest New Drugs; 2012 Feb; 30(1):25-36. PubMed ID: 20680659
[TBL] [Abstract][Full Text] [Related]
51. Requirement of histone deacetylase activity for signaling by STAT1.
Klampfer L; Huang J; Swaby LA; Augenlicht L
J Biol Chem; 2004 Jul; 279(29):30358-68. PubMed ID: 15123634
[TBL] [Abstract][Full Text] [Related]
52. An intact immune system is required for the anticancer activities of histone deacetylase inhibitors.
West AC; Mattarollo SR; Shortt J; Cluse LA; Christiansen AJ; Smyth MJ; Johnstone RW
Cancer Res; 2013 Dec; 73(24):7265-76. PubMed ID: 24158093
[TBL] [Abstract][Full Text] [Related]
53. Inhibition of Histone Deacetylase Activity Aggravates Coxsackievirus B3-Induced Myocarditis by Promoting Viral Replication and Myocardial Apoptosis.
Zhou L; He X; Gao B; Xiong S
J Virol; 2015 Oct; 89(20):10512-23. PubMed ID: 26269170
[TBL] [Abstract][Full Text] [Related]
54. BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing.
Martin AP; Park MA; Mitchell C; Walker T; Rahmani M; Thorburn A; Häussinger D; Reinehr R; Grant S; Dent P
Mol Pharmacol; 2009 Aug; 76(2):327-41. PubMed ID: 19483105
[TBL] [Abstract][Full Text] [Related]
55. Effect of trichostatin A on Burkitt's lymphoma cells: Inhibition of EPS8 activity through Phospho-Erk1/2 pathway.
Sun P; Zhou X; He Y; Liu H; Wang Y; Chen Y; Li M; He Y; Li G; Li Y
Biochem Biophys Res Commun; 2018 Mar; 497(4):990-996. PubMed ID: 29462617
[TBL] [Abstract][Full Text] [Related]
56. Epigenetic changes in tumor Fas levels determine immune escape and response to therapy.
Maecker HL; Yun Z; Maecker HT; Giaccia AJ
Cancer Cell; 2002 Aug; 2(2):139-48. PubMed ID: 12204534
[TBL] [Abstract][Full Text] [Related]
57. Inactivation of NF-kappaB by proteasome inhibition contributes to increased apoptosis induced by histone deacetylase inhibitors in human breast cancer cells.
Domingo-Domènech J; Pippa R; Tápia M; Gascón P; Bachs O; Bosch M
Breast Cancer Res Treat; 2008 Nov; 112(1):53-62. PubMed ID: 18064564
[TBL] [Abstract][Full Text] [Related]
58. Histone acetylation regulates the cell type specific CIITA promoters, MHC class II expression and antigen presentation in tumor cells.
Chou SD; Khan AN; Magner WJ; Tomasi TB
Int Immunol; 2005 Nov; 17(11):1483-94. PubMed ID: 16210330
[TBL] [Abstract][Full Text] [Related]
59. Effects of Histone Deacetylase Inhibitor (HDACi); Trichostatin-A (TSA) on the expression of housekeeping genes.
Mogal A; Abdulkadir SA
Mol Cell Probes; 2006 Apr; 20(2):81-6. PubMed ID: 16326072
[TBL] [Abstract][Full Text] [Related]
60. In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma.
Maes K; De Smedt E; Kassambara A; Hose D; Seckinger A; Van Valckenborgh E; Menu E; Klein B; Vanderkerken K; Moreaux J; De Bruyne E
Oncotarget; 2015 Feb; 6(5):3319-34. PubMed ID: 25669970
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
